Survival from relapse was short despite intensive treatment, especially chemotherapy, given in these transplanted patients. CNS relapse probably emerged from resistant plasma cells which escaped the cytoreductive chemotherapy and conditioning regimen. In fact, high-dose melphalan, the main drug of inensive treatment in myeloma, does not cross the blood-brain barrier. [10] [11] [12] [13] Taken together, these observations suggest that neuro-meningeal prophylaxis including cranial radiotherapy should be part of the intensive treatment of primary PCL. The best intrathecal prophylaxis would have to be determined. Intrathecal methotrexate and cytarabine, which are effective in the treatment of leukemic meningitis, are not efficacious for myelomatous meningitis.
14 Nevertheless, they could have a role as prophylaxis, especially cytarabine. In patient 2, cytarabine, given intrathecally and as part of the EDAP protocol, probably contributed to the transient normalization of the cerebrospinal fluid. Thiotepa, which is a cell cycle-insensitive alkaylting agent has also been given by the intrathecal route for treatment of meningeal myelomatosis and could be proposed for prophylaxis. 15 Finally, these reports raise the issue of routine cerebrospinal fluid examination and CNS magnetic resonance imaging in patients with primary PCL at diagnosis. clinical status of B lineage ALL patients (HLA-DR + ,CD19 + , n = 16) followed up longitudinally for 3 years.
ALL patients, who received treatment as per the UKALLVIII protocol, were bled at different phases of therapy. Peripheral blood mononuclear cells were isolated and cultured with ATN H (0.05-12 g) for 96 h followed by an 18 h pulse with 3 H-TdR. Radioactivity incorporated, in individual samples, was plotted against ATN H dose and the dose corresponding to maximal incorporation of radioactivity was designated as its 'maximal lymphoproliferative dose' (MLD). The MLD was employed to evaluate the percentage recovery of individual patients.
The variation in MLD values for individual patients, under different phases of treatment is shown in Table 1 and employed as an index to determine their % recovery. The pretreatment MLD, for all patients, ranging from 0.1 to 0.25 g, represented 0% recovery and reflected a possible increased expression of 9-OAcSGs. Following therapy, the MLD progressively increased to 1-2 g during consolidation/early intensification (4-8 weeks) and 3-8 g in maintenance therapy (8 weeks-2 years). The increasing MLD indicated an increase in % recovery and a possible decline in expression of 9-OAcSGs. In contrast, following relapse, the MLD sharply decreased, stating a decline in % recovery and reinduced expression of 9-OAcSGs. On an individual basis, for example, patient No. 2 showed MLD of 0.25 g, 2.0 g, 3.0 g, 8.0 g and 8.0 g in the 0, 5th, 9th, 20th and 64th weeks of treatment corresponding to a recovery of 1.52%, 19.20%, 29.30%, 79.80% and 79.80%. However, in the 72nd and 80th weeks the MLD sharply decreased to 2.0 g and 0.1 g reflecting relapse, corroborated by clinico-morphological features. Normal donors (n = 30) showed a high MLD (10.00 ± 0.01 g) suggesting a low expression of 9-OAcSGs, consistent with earlier observations. 2, 3 We therefore hypothesize that MLD bears an inverse relation with expression of 9-OAcSGs and can serve as a direct measure of % recovery (r = +0.76) of individual patients following therapy.
In the study population (n = 16), two patients (Nos 15 and 16, 2/16), with their MLD continually persisting at 8 g, stayed in long-term remission, one (1/16) did not respond to treatment, while 13 (13/16) relapsed (Table 1 ). The relapse rate was 44% during maintenance therapy (Nos 2, 3, 5, 6, 9, 12, 13) and 19% after completion of therapy (Nos 1, 4, 7). Patients 8, 11 and 14 (19%), with a persistent low MLD (р4 g), relapsed prior to maintenance therapy, although no leukemic blasts were morphologically detected. Patient No. 10 showed a poor chemotherapeutic response as was evident by persistent low MLD and the presence of leukemic blasts. The higher incidence of relapse observed in our study may be attributed to the inclusion of patients irrespective of their risk factors, higher male:female ratio (7:1), also malnutrition and concurrent infection which serve as predominant guiding factors in prognostic evaluation of children with ALL in developing countries. 4, 5 Interestingly, the lymphoproliferation assay could predict relapse in patients 1, 2, 3, 4, 6, 7, 8, 11, 12 and 14 (10/13) even when leukemic blasts were below the limits of cytomorphological resolution. However, relapse could not be predicted in patients 5, 9 and 13 (3/13) before its morphological detection since they did not come for regular follow-up after attaining remission (MLD = 8 g).
To summarize, our study suggests that regular, frequent monitoring of MLD, using a noninvasive lymphoproliferation assay, may be used to assess the clinical status of patients at different stages of treatment and could potentially improve risk assessment strategies in the management of ALL. We recommend that patients with low MLD should be closely monitored for disease resurgence. Additionally, low-dose therapy may be considered for patients showing a persisting high MLD (8 g). Comparison of lymphoproliferation assay with PCR, immunophenotyping and cytomorphological studies, in a large study population, would further validate its application as a novel strategy in ALL research. Such studies are currently underway.
ing ATRA treatment. 3 Some authors referred to an increased expression of adhesion molecules such as VCAM, CD11a, CD11b in polymorphonuclear cells from coronaric sinus of patients with unstable angina. 4 Whether this phenomenon might be primitive (and thus potentially crucial in the destabilization of an atheromasic plaque) or secondary to a disreactive, as well as inflammatory status, is at present unknown. In vitro studies indicate that ATRA is capable of inducing in APL cells the expression of the same adhesion molecules which have been locally found overexpressed in patients with unstable angina. 5 If this overexpression receives an in vivo confirmation during ATRA treatment, ATRA in APL patients could be responsible in predisposing patients to pathologic conditions similar to those observed during unstable angina.
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